AIM ImmunoTechAIM -1.99%33 3-Year ROIIC % is 595.03 as of Dec. 2025, which is 529% above its 10-year median of 94.64. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.59 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,319 Biotechnology companies, AIM ImmunoTech ranks better than 91.36% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
AIM ImmunoTech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 595.03%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for AIM ImmunoTech's 3-Year ROIIC % or its related term are showing as below:
AIM's 3-Year ROIIC % is ranked better than 91.36% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs AIM: 595.03
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
AIM ImmunoTech 3-Year ROIIC % Related Terms
AIM ImmunoTech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM vs RVPH, BOLT, ERNA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, AIM ImmunoTech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's 3-Year ROIIC % falls into.
AIM ImmunoTech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -11.664 (Dec. 2025) - -19.923 (Dec. 2022) )
/
( 6.504 (Dec. 2025) - 5.116 (Dec. 2022) )
=
8.259
/
1.388
=
595.03%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
AIM ImmunoTech (AIM) has a 3-Year ROIIC % of 595.03 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on AIM ImmunoTech and its competitors. This is 529% above median its historical median of 94.64. According to the industry distribution chart, AIM ImmunoTech ranks #114 out of 1319 companies in the Biotechnology industry, placing it in the top 8.6%.
Is AIM ImmunoTech's 3-Year ROIIC % too high?
AIM ImmunoTech's current 3-Year ROIIC % of 595.03 is 529% above median its 10-year median of 94.64. Based on the distribution chart, AIM ImmunoTech ranks #114 out of 1319 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's 3-Year ROIIC % compare to RVPH and BOLT?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #114 out of 1319 companies for 3-Year ROIIC %. This places AIM ImmunoTech in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current 3-Year ROIIC % is 595.03, which is 529% above median its own 10-year median of 94.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.59, compared to a current price of $0.29 — trading 88.8% below its estimated fair value. The current 3-Year ROIIC % is 595.03, which is 529% above median its 10-year median of 94.64. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current 3-Year ROIIC % is 595.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.29 is trading 88.8% below its estimated GF Value™ of $2.59.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
3-Year ROIIC %: 595.03 (529% above median its 10-year median of 94.64)
GF Value™: $2.59 vs. price of $0.29 (88.8% below fair value)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
